Oncology PracticeBenefits and drawbacks found for risk-based lung cancer screening toolsDecember 6, 2019Lung Cancer
Oncology PracticePatient-reported outcomes support first-line pembrolizumab for NSCLCDecember 6, 2019Lung CancerImmuno-oncology
Oncology PracticeFDA approves atezolizumab combo as first line for advanced NSCLCDecember 4, 2019Lung Cancer
Oncology PracticeSingle-fraction radiation just misses mark for spinal compression reliefDecember 4, 2019Breast CancerLung CancerGenitourinary Cancer
Oncology PracticeLarge state disparities seen for lung cancer screeningDecember 2, 2019Lung CancerPreventive Care
Oncology PracticeNeoantigen vaccine appears safe and active in NSCLCNovember 14, 2019Lung CancerImmunotherapyImmuno-oncology
Oncology PracticeLorlatinib induces deep responses in ROS1-positive NSCLCNovember 13, 2019Lung Cancer
‘You had me at hello’: ESMO studies confirm survival benefits in NSCLC and breast cancerNovember 11, 2019Lung CancerBreast Cancer
Oncology PracticeAtezolizumab bests chemo in NSCLC patients with high PD-L1 expressionNovember 10, 2019Lung CancerImmunotherapy
Oncology PracticeLung cancer on the decline, but still higher among men than womenNovember 8, 2019Lung Cancer
Oncology PracticeNivolumab benefit for NSCLC persists at 5-year follow-upNovember 6, 2019Lung CancerImmuno-oncology
Oncology PracticeFluoroscopic system can improve targeting of lung lesionsNovember 4, 2019Lung Cancer
Oncology PracticeLevothyroxine dose for checkpoint inhibitor toxicity may be too highNovember 4, 2019MelanomaLung CancerPatient & Survivor CareImmunotherapy
